Moxibustion treatment for diarrhea-predominant irritable bowel syndrome: study protocol for a randomized controlled trial

BMC Complementary and Alternative Medicine

Study Protocol

Zhihai Hu¹  Jing Li²  Xiaoqing Zeng³  Huirong Liu⁴  Huangan Wu⁴  Jinmei Liu⁴  Jingzhi Zhang⁴  Luyi Wu⁴  Siyao Wang⁴  Chunhui Bao⁴  Yongzheng Dong⁴  Yin Shi⁵ 

[1] Department of Acupuncture-Moxibustion, Shanghai Traditional Chinese Medicine-Integrated Hospital, Shanghai University of Traditional Chinese Medicine, 200082, Shanghai, China;Department of Acupuncture-Moxibustion, Yueyang Integrated Chinese and Western Medicine Hospital, Shanghai University of Traditional Chinese Medicine, 200437, Shanghai, China;Department of Gastroenterology, Zhongshan Hospital, Fudan University, 200032, Shanghai, China;Key Laboratory of Acupuncture and Immunological Effects, Shanghai University of Traditional Chinese Medicine, 650 South Wanping Road, 200030, Shanghai, China;Outpatient Department, Shanghai Research Institute of Acupuncture and Meridian, Shanghai University of Traditional Chinese Medicine, 200030, Shanghai, China;

关键词: Diarrhea;    Irritable bowel syndrome;    Moxibustion;    Randomized controlled trial;   

DOI  :  10.1186/s12906-016-1386-4

 received in 2016-05-17, accepted in 2016-10-18,  发布年份 2016

来源: Springer

【 摘 要 】

BackgroundIrritable bowel syndrome (IBS) is a worldwide disease with high morbidity. The effect of current treatment with Western medicine is not satisfactory. Although moxibustion treatment is widely used for gastrointestinal diseases, randomized controlled trials on the use of this treatment for IBS are limited. This study aims to evaluate the clinical efficacy and safety of moxibustion treatment in patients with diarrhea-predominant irritable bowel syndrome (IBS-D).Methods/designA multi-center, randomized, single-blind and placebo-controlled trial is employed. 104 cases will be divided into two groups: (1) a mild-warm moxibustion group in which moxa stick is 3–5 cm away from acupuncture points and the skin temperature is maintained at 43 ± 1 °C; and (2) a placebo moxibustion group in which moxa stick is 8–10 cm away from acupuncture points and the skin temperature is maintained at 37 ± 1 °C. Moxibustion is performed on bilateral ST25 and ST36 in the two groups for 30 min each time, three times a week for 6 weeks. The patients are followed up at the 12th and 18th weeks. Adequate relief is used as a primary outcome measure; IBS symptom severity score, Bristol stool form scale, IBS quality-of-life questionnaire, and hospital anxiety and depression scale are used as secondary outcome measures.DiscussionThis study aims to demonstrate the safety and efficacy of moxibustion treatment for IBS-D, which may validate moxibustion as an effective therapy for treating IBS-D.Trial registrationClinicalTrials.gov identifier NCT02421627 (8 April 2015).

【 授权许可】

CC BY   
© The Author(s). 2016